Yousef Mohammad Almoghrabi

Dr. Yousef Mohammad Almoghrabi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2023 in Medicina
Verified
Journal Article
Open access
PDF file
YAYazeed Abdullah Alshuweishi
Yazeed Abdullah Alshuweishi
MAMohammed Hussain Alfaifi
Mohammed Hussain Alfaifi
YAYousef Mohammad Almoghrabi
Yousef Mohammad Almoghrabi
YAYazeed Al-Sheikh
Yazeed Al-Sheikh
Mohammad A. AlfhiliMohammad A. Alfhili
Mohammad A. Alfhili
Background: The link between inflammation and anemia is well established but fluctuations in the emerging inflammatory index, neutrophil–lymphocyte ratio (NLR), in anemic subjects remain ambiguous. The purpose of this study is to address the prevailing knowledge gaps regarding the association of NLR with anemia in the Saudi population. Methods: Laboratory results of NLR, C-reactive protein (CRP), and hemoglobin for 14,261 subjects were obtained from Al Borg Diagnostics and retrospectively analyzed. Means, risk measures, and the diagnostic performance of NLR for anemia were examined in age- and gender-wise comparisons. Results: NLR was significantly elevated in anemic individuals and those with high NLR had a significantly lower Hb concentration. Moreover, elevated NLR was more prevalent in anemic subjects (PR: 1.87, 95% CI: 1.46–2.40, p < 0.0001) and carried a greater risk for the condition (OR: 1.91, 95% CI: 1.47–2.48, p < 0.0001) as did CRP. These observations demonstrated distinct age- and gender-specific patterns. However, both parameters were of no value in the diagnosis of anemia as seen from receiver operating characteristic curves. Conclusions: Altogether, these findings indicate that elevated NLR is associated with anemia, which suggests its usefulness for monitoring rather than diagnosing anemia associated with inflammation in Saudi subjects. Further examination of this association in longitudinal studies is needed.

4 August 2023 in Life
Verified
Journal Article
Open access
PDF file
Mohammad A. AlfhiliMohammad A. Alfhili
Mohammad A. Alfhili
GAGhada Alotaibi
Ghada Alotaibi
MAMohammed Hussain Alfaifi
Mohammed Hussain Alfaifi
YAYousef Mohammad Almoghrabi
Yousef Mohammad Almoghrabi
JAJawaher Alsughayyir
Jawaher Alsughayyir
Background: Abnormal lipid metabolism predisposes to cardiovascular disease. However, dyslipidemia is often asymptomatic leading to its underdiagnosis. Therefore, it is of utmost importance to identify biomarkers that reflect an abnormal lipid profile and trigger the specific investigation of lipid metabolism. The platelet–monocyte ratio (PMR) is a severely understudied index whose association with disturbed lipid markers remains unknown. Methods: A cross-sectional study of the association between PMR and comprehensive lipid profile including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), TC/HDL, LDL/HDL, and TG/HDL in 14,269 Saudi subjects was designed. Prevalence, risk measures, association, and the diagnostic performance (i.e., area under the curve (AUC)) were evaluated. Results: Median PMR was significantly elevated in subjects with high TC (p < 0.01), TG, TC/HDL, LDL/HDL, TG/HDL, and LDL and reduced in those with low HDL (all p < 0.0001) compared to normal subjects. The increase in PMR was abolished when only males with high TC were considered. Except for TC and LDL, all other abnormal markers were significantly more prevalent when PMR was lower (higher for HDL) than a certain cutoff specific for each parameter. Moreover, the odds of having PMR readings above or below the selected cutoffs are significantly higher with all lipid abnormalities. PMR was also weakly but significantly and differentially correlated with all forms of dyslipidemia (p < 0.0001). Notably, the highest diagnostic accuracy of PMR was observed for reduced HDL (AUC = 0.608, p < 0.0001) and elevated TG/HDL (AUC = 0.596, p < 0.0001). Conclusions: PMR is a novel, inexpensive, and readily available index that is associated with all forms of dyslipidemia, suggesting its potential use in related disorders.

7 September 2023 in Life
Verified
Journal Article
Open access
PDF file
YAYazeed Abdullah Alshuweishi
Yazeed Abdullah Alshuweishi
MAMohammed Hussain Alfaifi
Mohammed Hussain Alfaifi
YAYousef Mohammad Almoghrabi
Yousef Mohammad Almoghrabi
Mohammad A. AlfhiliMohammad A. Alfhili
Mohammad A. Alfhili
Background: Hyperglycemia is a common symptom of numerous conditions, most notably diabetes mellitus and Cushing’s syndrome, and the liver plays a pivotal role in the regulation of glucose metabolism. The AST–platelet ratio index (AST APRI score) and ALT–platelet ratio index (ALT APRI score) are novel parameters whose association with circulating glucose levels remains poorly studied. Methods: Laboratory data of 14,177 subjects were retrospectively analyzed for the association between AST and ALT APRI scores and fasting blood glucose (FBG) using the Mann–Whitney U and Kruskal–Wallis tests, Spearman’s rank correlation coefficient, prevalence and odds ratio (OR) and ROC curve analysis. Results: AST and ALT APRI scores showed progressive increases with FBG, and the mean FBG was significantly higher in subjects with high AST (104.9 ± 0.33 to 120.8 ± 3.27, p < 0.0001) and ALT (104.7 ± 0.34 to 111.6 ± 1.30, p < 0.0001) APRI scores. However, the AST APRI score but not the ALT APRI score was affected by age and gender. Notably, both elevated AST and ALT APRI scores were more prevalent in hyperglycemic subjects irrespective of gender and were associated with FBG, albeit through mediator variables. Increased AST (OR = 2.55, 95% CI: 1.46–2.06, p < 0.0001) and ALT (OR = 1.73, 95% CI: 1.46–2.06, p < 0.0001) APRI scores carried a significantly higher risk for hyperglycemia. Importantly, the ALT APRI score was superior to that of the AST APRI score in distinguishing hyperglycemic subjects. Conclusions: The AST and ALT APRI scores are inexpensive, novel markers of FBG and may serve as supportive evidence in the diagnosis and management of hyperglycemic conditions.

27 January 2025 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
Basmah Medhat EldakhakhnyBasmah Medhat Eldakhakhny
Basmah Medhat Eldakhakhny
FGFatma M. Ghoneim
Fatma M. Ghoneim
MSMona F. M. Soliman
Mona F. M. Soliman
SESalwa Abo El-khair
Salwa Abo El-khair
AEAyman Zaky Elsamanoudy
Ayman Zaky Elsamanoudy
AAAmany AbdElfattah
Amany AbdElfattah